{"id":478218,"date":"2020-04-07T11:58:01","date_gmt":"2020-04-07T11:58:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=478218"},"modified":"2020-04-07T11:58:01","modified_gmt":"2020-04-07T11:58:01","slug":"dry-eye-disease-clinical-trial-insight-pipeline-assessment-emerging-drugs-delveinsight","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/dry-eye-disease-clinical-trial-insight-pipeline-assessment-emerging-drugs-delveinsight_478218.html","title":{"rendered":"Dry Eye Disease Clinical Trial Insight, Pipeline Assessment, Emerging Drugs | DelveInsight"},"content":{"rendered":"
\"Dry<\/a><\/p>\n
\n
Dry eye disease Pipeline Insight, 2020<\/div>\n<\/div>\n<\/div>\n

DelveInsight launched a new report on “Dry eye disease Pipeline Insight, 2020”<\/a>.<\/p>\n

“Dry eye disease Pipeline Insight, 2020<\/strong>” report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Dry eye disease <\/strong>market. A detailed picture of the Dry eye disease <\/strong>pipeline landscape is provided, which includes the disease overview and Dry eye disease <\/strong>treatment guidelines. The assessment part of the report embraces in-depth Dry eye disease <\/strong>commercial assessment and clinical assessment of the Dry eye disease <\/strong>pipeline products from the pre-clinical developmental phase to the marketed phase. In the report, a detailed description of the drug is proffered including mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Dry eye disease <\/strong>collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.<\/p>\n

The launch of the emerging therapies is expected to significantly impact Dry Eye Disease<\/em><\/strong> treatment scenario in the upcoming years:-
Drugs covered<\/p>\n

    \n
  1. OC\u201001\/OC\u201002<\/li>\n
  2. OCU 310<\/li>\n
  3. HMB9036<\/li>\n
  4. Visomitin<\/li>\n
  5. RGN\u2010295<\/li>\n
  6. Travilermide ophthalmic solution<\/li>\n
  7. KPI\u2010121<\/li>\n<\/ol>\n

    And many others<\/p>\n

    The key players in Dry Eye Disease<\/em><\/strong> market are:<\/p>\n

      \n
    1. Oyster Point Pharma<\/li>\n
    2. Ocugen<\/li>\n
    3. HanAI Biopharma<\/li>\n
    4. Mitotech Pharma<\/li>\n
    5. ReGen Tree<\/li>\n
    6. Mimetogen Pharmaceuticals<\/li>\n
    7. Kala Pharmaceuticals<\/li>\n<\/ol>\n

      And many others<\/p>\n

       <\/strong><\/p>\n

      Request for sample pages :<\/strong> https:\/\/delveinsight.com\/sample-request\/dry-eye-disease-pipeline-insight<\/a><\/p>\n

       <\/strong><\/p>\n

      Dry eye disease Analytical Perspective by DelveInsight<\/strong><\/p>\n